95 related articles for article (PubMed ID: 21521022)
21. Molecular biomarkers: a US FDA effort.
Hong H; Goodsaid F; Shi L; Tong W
Biomark Med; 2010 Apr; 4(2):215-25. PubMed ID: 20406066
[TBL] [Abstract][Full Text] [Related]
22. Mouse Population-Based Approaches to Investigate Adverse Drug Reactions.
Mosedale M
Drug Metab Dispos; 2018 Nov; 46(11):1787-1795. PubMed ID: 30045843
[TBL] [Abstract][Full Text] [Related]
23. Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.
Almoguera B; Riveiro-Alvarez R; Gomez-Dominguez B; Lopez-Rodriguez R; Dorado P; Vaquero-Lorenzo C; Dal-Ré R; Fernandez-Piqueras J; Llerena A; Abad-Santos F; Ayuso C
Pharmacogenomics; 2010 Nov; 11(11):1619-25. PubMed ID: 21121779
[TBL] [Abstract][Full Text] [Related]
24. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
[TBL] [Abstract][Full Text] [Related]
25. A multistep validation process of biomarkers for preclinical drug development.
Freeman WM; Bixler GV; Brucklacher RM; Lin CM; Patel KM; VanGuilder HD; LaNoue KF; Kimball SR; Barber AJ; Antonetti DA; Gardner TW; Bronson SK
Pharmacogenomics J; 2010 Oct; 10(5):385-95. PubMed ID: 19997081
[TBL] [Abstract][Full Text] [Related]
26. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.
Parmar S; Seeringer A; Denich D; Gärtner F; Pitterle K; Syrovets T; Ohmle B; Stingl JC
Pharmacogenomics; 2011 Apr; 12(4):503-14. PubMed ID: 21521023
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Issa AM
Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
[TBL] [Abstract][Full Text] [Related]
28. Adverse drug reactions - allergy? side-effect? intolerance?
Smith W
Aust Fam Physician; 2013; 42(1-2):12-6. PubMed ID: 23529453
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers in aquatic plants: selection and utility.
Brain RA; Cedergreen N
Rev Environ Contam Toxicol; 2009; 198():49-109. PubMed ID: 19253039
[TBL] [Abstract][Full Text] [Related]
30. Sample size for FDR-control in microarray data analysis.
Jung SH
Bioinformatics; 2005 Jul; 21(14):3097-104. PubMed ID: 15845654
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of drugs withdrawn from the market.
Zhang W; Roederer MW; Chen WQ; Fan L; Zhou HH
Pharmacogenomics; 2012 Jan; 13(2):223-31. PubMed ID: 22256871
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
33. A GMM-IG framework for selecting genes as expression panel biomarkers.
Wang M; Chen JY
Artif Intell Med; 2010; 48(2-3):75-82. PubMed ID: 20004087
[TBL] [Abstract][Full Text] [Related]
34. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
[TBL] [Abstract][Full Text] [Related]
35. [Role of biomarkers in toxicity treatment "metabonomics" as a new biomarker discovery method].
Naraoka H; Suzumura K; Takeuchi K; Sasayama T
Rinsho Byori; 2008 Apr; 56(4):335-42. PubMed ID: 18516969
[TBL] [Abstract][Full Text] [Related]
36. Is premarket identification of hepatotoxic drugs and sensitive patients possible based on high-dimensional 'omic data?
Kodell RL; Chen JJ
Per Med; 2010 Mar; 7(2):171-178. PubMed ID: 29783321
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers-A General Review.
Aronson JK; Ferner RE
Curr Protoc Pharmacol; 2017 Mar; 76():9.23.1-9.23.17. PubMed ID: 28306150
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers as a tool for management of immunosuppression in transplant patients.
Wieland E; Olbricht CJ; Süsal C; Gurragchaa P; Böhler T; Israeli M; Sommerer C; Budde K; Hartmann B; Shipkova M; Oellerich M
Ther Drug Monit; 2010 Oct; 32(5):560-72. PubMed ID: 20814352
[TBL] [Abstract][Full Text] [Related]
39. Study design and statistical analysis of data in human population studies with the micronucleus assay.
Ceppi M; Gallo F; Bonassi S
Mutagenesis; 2011 Jan; 26(1):247-52. PubMed ID: 21164209
[TBL] [Abstract][Full Text] [Related]
40. Sample size calculation with dependence adjustment for FDR-control in microarray studies.
Shao Y; Tseng CH
Stat Med; 2007 Oct; 26(23):4219-37. PubMed ID: 17328091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
